Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simulations Plus (FRA:SD3) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Simulations Plus Forward PE Ratio Related Terms
Simulations Plus Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Simulations Plus's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simulations Plus Forward PE Ratio Chart
Simulations Plus Annual Data
Trend
2016-08
2017-08
2018-08
2019-08
2020-08
2021-08
Forward PE Ratio
25.06
35.59
38.76
58.14
87.72
75.19
Simulations Plus Quarterly Data
2016-02
2016-05
2016-08
2016-11
2017-02
2017-05
2017-08
2017-11
2018-02
2018-05
2018-08
2018-11
2019-02
2019-05
2019-08
2019-11
2020-02
2020-05
2020-08
2020-11
2021-02
2021-08
2026-02
2026-05
Forward PE Ratio
28.41
22.94
25.06
30.67
31.06
33.00
35.59
40.65
41.15
37.88
38.76
36.90
46.73
42.74
58.14
64.94
60.98
82.64
87.72
105.26
119.05
75.19
21.96
35.47
FRA:SD3 vs CTEV, TBRG, CARL: Forward PE Ratio Comparison
For the Health Information Services subindustry, Simulations Plus's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simulations Plus Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Simulations Plus's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Simulations Plus's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Simulations Plus (FRA:SD3) has a Forward PE Ratio of 38.35 as of Aug. 19, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Simulations Plus and its competitors. According to the industry distribution chart, Simulations Plus ranks #260 out of 316 companies in the Healthcare Providers & Services industry, placing it in the top 82.3%.
Is Simulations Plus' Forward PE Ratio too high?
Simulations Plus' current Forward PE Ratio is 38.35. The Healthcare Providers & Services industry median Forward PE Ratio is 18.87. Simulations Plus' value of 38.35 is 103.3% above this industry median. Based on the distribution chart, Simulations Plus ranks #260 out of 316 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Simulations Plus has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' Forward PE Ratio compare to CTEV and TBRG?
According to the Healthcare Providers & Services industry distribution chart, Simulations Plus ranks #260 out of 316 companies for Forward PE Ratio. This places Simulations Plus in the lower half of its industry. The industry median Forward PE Ratio is 18.87. Simulations Plus' value of 38.35 is 103.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.87, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simulations Plus's current Forward PE Ratio of 38.35 is 103.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Simulations Plus and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simulations Plus's current Forward PE Ratio is 38.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Simulations Plus (FRA:SD3) has a current Forward PE Ratio of 38.35. The stock's GF Value™ is €29.72, compared to a current price of €15.50 — trading 47.8% below its estimated fair value. The current Forward PE Ratio is 38.35 and 103.3% above the Healthcare Providers & Services industry median of 18.87. Simulations Plus' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Simulations Plus (FRA:SD3), the current Forward PE Ratio is 38.35 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simulations Plus (FRA:SD3) Overvalued in 2026?
Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued.
The current stock price of €15.50 is trading 47.8% below its estimated GF Value™ of €29.72.
Key valuation signals for FRA:SD3:
Forward PE Ratio: 38.35
GF Value™: €29.72 vs. price of €15.50 (47.8% below fair value)
Industry Position: 103.3% above the Healthcare Providers & Services median (#260 of 316)
No single metric tells the full story. See the FRA:SD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
82GF Score
Get the complete analysis for FRA:SD3
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SD3 has been successfully added to your 
